^
BIOMARKER:

ER Y537S

i
Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
Entrez ID:
Phase 1/2
H3 Biomedicine Inc.
Recruiting
Last update posted :
04/12/2022
Initiation :
08/17/2017
Primary completion :
06/30/2023
Completion :
06/30/2023
HER-2 • ER
|
ER positive • HER-2 negative • ER Y537S • ER D538G • ESR1 mutation
|
H3B-6545
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
03/17/2022
Initiation :
05/31/2019
Primary completion :
04/26/2023
Completion :
04/26/2024
ER • PGR
|
ER positive • HR positive • ER mutation • ER Y537S • ER D538G • ESR1 mutation
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole
Phase 2
Sermonix Pharmaceuticals Inc.
Active, not recruiting
Last update posted :
08/26/2021
Initiation :
09/20/2019
Primary completion :
02/01/2022
Completion :
02/01/2022
HER-2 • ER
|
HER-2 negative • ER mutation • ER Y537S • ER D538G • ER Y537N • ESR1 mutation • ER L536Q • ER Y537C
|
fulvestrant • Fablyn (lasofoxifene)
Phase 2
Sermonix Pharmaceuticals Inc.
Active, not recruiting
Last update posted :
07/02/2021
Initiation :
09/29/2020
Primary completion :
05/01/2022
Completion :
10/01/2022
HER-2 • ER
|
HER-2 negative • ER mutation • ER Y537S • ER D538G • ER Y537N • ESR1 mutation • ER L536Q • ER Y537C
|
Verzenio (abemaciclib) • Fablyn (lasofoxifene)
Phase 2
Fudan University
Not yet recruiting
Last update posted :
06/29/2017
Initiation :
07/01/2017
Primary completion :
06/01/2019
Completion :
08/01/2019
ER • PGR
|
ER mutation • ER Y537S • ER D538G • ER Y537N • ESR1 mutation • ER Y537C
|
fulvestrant